Radioimmunotherapy with I-131-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Yoon Jung | - |
dc.contributor.author | Lim, Sang Moo | - |
dc.contributor.author | Lee, Inki | - |
dc.contributor.author | Byun, Byung Hyun | - |
dc.contributor.author | Lim, Ilhan | - |
dc.contributor.author | Kim, Byung Il | - |
dc.contributor.author | Choi, Chang Woon | - |
dc.contributor.author | Lee, Seung-Sook | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Kong, Jee Hyun | - |
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Oh, Suk Joong | - |
dc.contributor.author | Park, Keon Woo | - |
dc.contributor.author | Han, Jae Joon | - |
dc.contributor.author | Song, Moo-Kon | - |
dc.contributor.author | Yang, Sung Hyun | - |
dc.contributor.author | Na, Im Il | - |
dc.contributor.author | Lee, Hyo-Rak | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.date.accessioned | 2023-08-07T02:40:37Z | - |
dc.date.available | 2023-08-07T02:40:37Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.issn | 1743-7563 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22566 | - |
dc.description.abstract | AimThis study aimed to evaluate the safety and efficacy of I-131-rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma. MethodsTwenty-four patients with relapsed or refractory follicular or mantle cell lymphoma were administered unlabeled rituximab (70 mg) immediately before receiving a therapeutic dose of I-131-rituximab. Contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography was used a month later to assess tumor response. ResultsThis study enrolled 24 patients between June 2012 and 2022. Depending on how they responded to radioimmunotherapy (RIT), I-131-rituximab was administered one to five times. Of the 24 patients, 9 achieved complete response after RIT and 8 achieved partial response. The median progression-free and overall survival was 5.9 and 37.9 months, respectively. During the follow-up period of 64.2 months, three patients were diagnosed with a secondary malignancy. Among treatment-related adverse events, hematologic toxicities were common, and grade 3-4 thrombocytopenia and neutropenia were reported in 66.6% of cases. Conclusion(131)I-rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Pub. Asia | - |
dc.title | Radioimmunotherapy with I-131-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/ajco.13932 | - |
dc.identifier.scopusid | 2-s2.0-85150624200 | - |
dc.identifier.wosid | 000948302800001 | - |
dc.identifier.bibliographicCitation | Asia-Pacific Journal of Clinical Oncology, v.19, no.6, pp 690 - 696 | - |
dc.citation.title | Asia-Pacific Journal of Clinical Oncology | - |
dc.citation.volume | 19 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 690 | - |
dc.citation.endPage | 696 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY | - |
dc.subject.keywordPlus | IODINE I-131 TOSITUMOMAB | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | TERM-FOLLOW-UP | - |
dc.subject.keywordPlus | LOW-GRADE | - |
dc.subject.keywordAuthor | 131I-rituximab | - |
dc.subject.keywordAuthor | follicular lymphoma | - |
dc.subject.keywordAuthor | mantle cell lymphoma | - |
dc.subject.keywordAuthor | phase II trial | - |
dc.subject.keywordAuthor | radioimmunotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.